AVXL
ANAVEX LIFE SCIENCES CORP.
NASDAQ · Healthcare · Biotechnology · US
$1.36
+8.80%Oct 15, 2026, 20:00 UTC
The U.S. Food and Drug Administration cleared Anavex Life Sciences' investigational new drug application for blarcamesine in Fragile X syndrome, allowing the company to proceed with a planned Phase 2a study in adult males.
Source:Oct 12, 2026, 06:17 UTC
A class action lawsuit alleging securities-law violations was filed against ANAVEX LIFE SCIENCES CORP.
Source:Oct 8, 2026, 14:11 UTC
A lawsuit involving ANAVEX LIFE SCIENCES CORP. has a lead plaintiff deadline of November 30, 2026.
Source:Oct 8, 2026, 07:00 UTC
A class action lawsuit was filed against ANAVEX LIFE SCIENCES CORP. on behalf of investors who acquired its securities during the stated class period.
Oct 1, 2026, 11:30 UTC
Grabar Law Office announced it is investigating whether certain officers and directors of Anavex Life Sciences Corp. breached their fiduciary duties owed to the company and its shareholders.
Source:Sep 30, 2026, 19:00 UTC
Anavex Life Sciences Corp. was sued for securities law violations, with the DJS Law Group inviting affected investors to discuss their rights.
Sep 30, 2026, 00:16 UTC
Rosen Law Firm filed a securities class action lawsuit on behalf of purchasers of Anavex Life Sciences Corp. securities for the class period November 26, 2025 to August 28, 2026, alleging false and misleading statements and inadequate internal controls.
Source:Sep 17, 2026, 16:17 UTC
Glass Lewis recommended that Anavex Life Sciences stockholders vote the GOLD universal proxy card, supporting PVG Asset Management's call for change by backing two of PVG's director nominees and opposing two incumbent director nominees including the board's current chair.
Source:Sep 14, 2026, 12:30 UTC
Institutional Shareholder Services recommended that Anavex Life Sciences stockholders vote for all six of the company's director nominees on the white proxy card at the 2026 Annual Meeting of Stockholders.
Source:Aug 25, 2026, 16:14 UTC
Anavex Life Sciences announced regulatory progress for its lead drug blarcamesine in Q3 2026.
Source:Aug 25, 2026, 00:00 UTC
Anavex Life Sciences Corp. reported a net income of $7.8 million for Q3 2026, compared with a net loss of $13.2 million in Q3 2025, with diluted EPS of $0.08.